NL-OMON21053
Recruiting
Not Applicable
Accuracy of detecting residual disease after chemoradiotherapy preceding surgery for oesophageal cancer
Erasmus MC – University Medical Center RotterdamAcademic Medical Center AmsterdamUniversity Medical Center UtrechtCatharina Cancer Center EindhovenAtrium Medical Center Heerlen0 sites120 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- English: Squamous cell- or adenocarcinoma of the oesophagus or oesophago-gastric junction.Dutch: Plaveiselcel- of adenocarcinoom van de slokdarm of gastro-oesophageale overgang.
- Sponsor
- Erasmus MC – University Medical Center RotterdamAcademic Medical Center AmsterdamUniversity Medical Center UtrechtCatharina Cancer Center EindhovenAtrium Medical Center Heerlen
- Enrollment
- 120
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who are planned to undergo neoadjuvant chemoradiotherapy according to CROSS, followed by surgical resection for histologically proven oesophageal squamous cell carcinoma or adenocarcinoma are eligible for this study.
Exclusion Criteria
- •Dementia or altered mental status prohibiting the understanding and giving of informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (PRESANO trial)carcinoma of the oesophagusoesophageal cancer100179901001799110017998NL-OMON43870Erasmus MC, Universitair Medisch Centrum Rotterdam215
Recruiting
Not Applicable
Response evaluation after neoadjuvant chemotherapy for muscle invasive bladder cancerNL-OMON25664ot applicable180
Completed
Not Applicable
The accuracy of detecting residual disease following neo-adjuvant chemotherapy in patients with muscle-invasive bladder cancerBladder cancerMuscle invasive urothelial cell carcinoma of the bladder10004994NL-OMON50035Vrije Universiteit Medisch Centrum180
Completed
Not Applicable
Prognostic Indicators for Conventional Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients in Resource-Limited CountrySCLC patients with unresectable stage IIIB or IV by TNM 7th edition who were treated with platinum-based doublet chemotherapy as first line treatmentnon small cell lung cancer, prognostic factor, chemotherapyTCTR20220131001A207
Active, not recruiting
Phase 1
A new magnetic resonance scanning technology for monitoring therapy effects in patients with Pancreatic cancer.Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]MedDRA version: 20.0Level: LLTClassification code 10033575Term: Pancreas cancerSystem Organ Class: 100000004864EUCTR2016-004491-22-DKDept. Clinical Medicine, Aarhus Universit15